Item 8.01 Other Events.
On January 26, 2021, Agios Pharmaceuticals, Inc. issued a press release
announcing that its global phase 3 ACTIVATE-T trial of mitapivat in adults with
pyruvate kinase deficiency who are regularly transfused met its primary
endpoint. The full text of the press release issued in connection with this
announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release issued January 26, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses